IP Library Patent Application 13537146
Patent Application
App. No. 13/537,146

Methods And Apparatus To Zero A Patient Trigger Sensor

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/537,146
Abstract

Described are methods and apparatus for therapeutic or medical gas delivery that reset or zero the trigger sensor used to detect patient inspiration and expiration. The trigger sensor may be reset automatically during patient expiration to avoid interfering with drug delivery or the breath detection algorithm.

Claims (52)

1 . A therapeutic gas delivery apparatus comprising:

a therapeutic gas delivery conduit in fluid communication with a nasal cannula or breathing apparatus to deliver a therapeutic gas to a patient when the delivery conduit is connected to a gas source;

a passageway in fluid communication with the nasal cannula or breathing apparatus;

a trigger sensor having a first side in fluid communication with the passageway and a second side in fluid communication with a differential pressure port in fluid communication with ambient air or a pressurized patient breathing mask, wherein the trigger sensor detects a positive or negative pressure differential between the passageway and the differential pressure port, to detect patient inspiration and expiration;

a first trigger zero valve in fluid communication with the passageway and the first side of the trigger sensor;

a second trigger zero valve in fluid communication with the differential pressure port and the second side of the trigger sensor;

a control system in communication with the first trigger zero valve and the second trigger zero valve that resets the trigger sensor during patient expiration.

2 . The apparatus of claim 1 , wherein the first trigger zero valve is a three-way valve having at least a first state and a second state, the first state enabling fluid communication between the passageway and the first side of the trigger sensor and the second state enabling fluid communication between the first side of the trigger sensor and a pressure source, and wherein the second trigger zero valve is a three-way valve having at least a first state and a second state, the first state enabling fluid communication between the differential pressure port and the second side of the trigger sensor and the second state enabling fluid communication between the second side of the trigger sensor and the pressure source.

3 . The apparatus of claim 2 , wherein the pressure source is ambient air.

4 . The apparatus of claim 2 , wherein the pressure source does not contain oxygen.

5 . The apparatus of claim 2 , wherein the second state of the first trigger zero valve prevents fluid communication between the passageway and the pressure source and the second state of the second trigger valve prevents fluid communication between the differential pressure port and the pressure source.

6 . The apparatus of claim 2 , wherein the control system, in communication with the first trigger zero valve and the second trigger zero valve, simultaneously sets the first and second trigger zero valves to their respective second states to make the pressure on the first side of the trigger sensor equal to the pressure on the second side of the trigger sensor.

7 . The apparatus of claim 6 , wherein the control system sets the first and second trigger zero valves to their respective second states during patient expiration.

8 . The apparatus of claim 6 , wherein the control system, in communication with the trigger sensor, sets the first and the second trigger zero valves to their respective second states when the trigger sensor detects a positive pressure differential between the passageway and the differential pressure port.

9 . (canceled)

10 . (canceled)

11 . (canceled)

12 . The apparatus of claim 1 , wherein the gas source comprises nitric oxide.

13 . A therapeutic gas delivery apparatus comprising:

a therapeutic gas delivery conduit in fluid communication with a nasal cannula or breathing apparatus and to deliver a therapeutic gas to a patient when the delivery conduit is connected to a gas source;

a passageway in fluid communication with the nasal cannula or breathing apparatus;

a trigger sensor having a first side in fluid communication with the passageway and a second side in fluid communication with a differential pressure port in fluid communication with ambient air or a pressurized patient breathing mask, wherein the trigger sensor detects a positive or negative pressure differential between the passageway and the differential pressure port;

a trigger zero valve in fluid communication with the first and second sides of the trigger sensor; and

a control system in communication with the trigger zero valve that resets the trigger sensor during patient expiration.

14 . The apparatus of claim 13 , wherein the trigger zero valve has at least a first state and a second state, the first state preventing fluid communication between the first and second sides of the trigger sensor and the second state enabling fluid communication between the first and second sides of the trigger sensor.

15 . The apparatus of claim 14 , wherein the control system, in communication with the trigger zero valve, controls whether the trigger zero valve is in the first state or the second state.

16 . The apparatus of claim 15 , wherein the control system sets the trigger zero valve to the second state during patient expiration.

17 . The apparatus of claim 15 , wherein the control system, in communication with the trigger sensor, sets the trigger zero valve to the second state when the trigger sensor detects a positive pressure differential between the passageway and the differential pressure port.

18 . The apparatus of claim 14 , wherein when the trigger zero valve is in the second state, the first and second sides of the trigger sensor are in fluid communication with a pressure source.

19 . The apparatus of claim 13 , wherein the gas source comprises nitric oxide.

20 . A method of administering therapeutic gas, the method comprising:

sensing inspiration of a patient using a trigger sensor detecting a pressure differential applied on the trigger sensor relative to ambient air or a pressurized patient breathing mask;

during patient inspiration, delivering a pulse of therapeutic gas to the patient with one or more control valves; and

resetting the trigger sensor with one or more trigger zero valves during patient expiration.

21 . The method of claim 20 , further comprising sensing expiration of the patient, and wherein the trigger sensor is reset during patient expiration.

22 . The method of claim 20 , wherein the trigger sensor is reset after a predetermined period of time since the last trigger sensor reset.

23 . The method of claim 20 , wherein resetting the trigger sensor comprises placing the one or more trigger zero valves in a state such that a first side and a second side of the trigger sensor are each in fluid communication with a pressure source so that the pressure on the first side of the trigger sensor is equal to the pressure on the second side of the trigger sensor.

24 . The method of claim 20 , wherein resetting the trigger sensor comprises placing a first side of the trigger sensor in fluid communication with a second side of the trigger sensor.

25 . The method of claim 20 , wherein the therapeutic gas comprises nitric oxide.

26 . The method of claim 20 , wherein the trigger sensor is reset automatically without patient intervention.

27 . The apparatus of claim 1 , wherein the therapeutic gas delivery conduit is in direct fluid communication with the nasal cannula or breathing apparatus and the passageway.

28 . The apparatus of claim 1 , further comprising:

a one or more control valves regulating flow of the therapeutic gas to the nasal cannula or breathing apparatus, the one or more control valves being in fluid communication with the therapeutic gas delivery conduit, the gas source, and the nasal cannula or breathing apparatus; and

wherein the one or more control valves is located between the gas source and the nasal cannula or breathing apparatus.

29 . The apparatus of claim 28 , wherein the nasal cannula or breathing apparatus is in fluid communication with the one or more control valves at a first offset distance and the trigger sensor at a second offset distance, the first offset distance being further from the nasal cannula or breathing apparatus than the second offset distance.

30 . The apparatus of claim 1 , wherein the control system, in communication with the trigger sensor and a one or more control valves, opens the one or more control valves during patient inspiration.

31 . The apparatus of claim 13 , wherein the therapeutic gas delivery conduit is in direct fluid communication with the nasal cannula or breathing apparatus and the passageway.

32 . The apparatus of claim 13 , further comprising:

a one or more control valves regulating flow of the therapeutic gas to the nasal cannula or breathing apparatus, the one or more control valves being in fluid communication with the therapeutic gas delivery conduit, the gas source, and the nasal cannula or breathing apparatus; and

wherein the one or more control valves is located between the gas source and the nasal cannula or breathing apparatus.

33 . The apparatus of claim 32 , wherein the nasal cannula or breathing apparatus is in fluid communication with the one or more control valves at a first offset distance and the trigger sensor at a second offset distance, the first offset distance being further from the nasal cannula or breathing apparatus than the second offset distance.

34 . The apparatus of claim 1 , wherein the control system, in communication with the trigger sensor and a one or more control valves, opens the one or more control valves during patient inspiration.

Assignments (11)
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 035454, FRAME 0768 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; THERAKOS, INC.; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065610/0035 →
SECURITY INTEREST Recorded Apr 19, 2015
From: INO THERAPEUTICS LLC
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 035454/0768 →
RELEASE OF SECURITY INTEREST Recorded Apr 17, 2015
From: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH
To: INO THERAPEUTICS LLC
Reel/Frame 035453/0487 →
RELEASE OF SECURITY INTEREST Recorded Apr 17, 2015
From: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH
To: INO THERAPEUTICS LLC
Reel/Frame 035453/0513 →
PATENT SECURITY AGREEMENT (FIRST LIEN) Recorded Mar 11, 2014
From: INO THERAPEUTICS LLC
To: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, AS ADMINISTRATIVE AGENT
Reel/Frame 032426/0747 →
PATENT SECURITY AGREEMENT (SECOND LIEN) Recorded Mar 11, 2014
From: INO THERAPEUTICS LLC
To: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, AS ADMINISTRATIVE AGENT
Reel/Frame 032426/0848 →
RELEASE OF SECURITY INTEREST Recorded Feb 18, 2014
From: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, AS COLLATERAL AGENT
To: INO THERAPEUTICS LLC
Reel/Frame 032274/0768 →
RELEASE OF SECURITY INTEREST Recorded Feb 14, 2014
From: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, AS COLLATERAL AGENT
To: IKARIA INC.; INO THERAPEUTICS LLC
Reel/Frame 032264/0517 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 27, 2013
From: ACKER, JARON; KOHLMANN, THOMAS
To: INO THERAPEUTICS LLC
Reel/Frame 031685/0923 →
SECURITY AGREEMENT Recorded Jul 10, 2013
From: IKARIA, INC.; IKARIA ACQUISITION INC.; INO THERAPEUTICS LLC
To: CREDIT SUISSE AG, AS COLLATERAL AGENT
Reel/Frame 030764/0549 →
SECURITY AGREEMENT Recorded Sep 21, 2012
From: INO THERAPEUTICS LLC
To: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, AS COLLATERAL AGENT
Reel/Frame 029026/0011 →